For patients with BRAF wild-type melanoma or those patients with BRAF mutations showing tumour progression after targeted therapy, immunotherapy (i.e. ipilimumab, nivolumab or pembrolizumab) is the standard treatment prior to chemotherapy. This evidence concerns the gene BRAF and melanoma.